This study examined the signaling events induced by shikonin that lead to the induction of apoptosis in Bcr/ Abl-positive chronic myelogenous leukemia (CML) cells (e.g., K562, LAMA84). Treatment of K562 cells with shikonin (e.g., 0.5 μM) resulted in profound induction of apoptosis accompanied by rapid generation of reactive oxygen species (ROS), striking activation of c-Jun-N-terminal kinase (JNK) and p38, marked release of the mitochondrial proteins cytochrome c and Smac/DIABLO, activation of caspase-9 and -3, and cleavage of PARP. Scavenging of ROS completely blocked all of the above-mentioned events (i.e., JNK and p38 phosphorylation, cytochrome c and Smac/DIABLO release, caspase and PARP cleavage, as well as the induction of apoptosis) following shikonin treatment. Inhibition of JNK and knock-down of JNK1 significantly attenuated cytochrome c release, caspase cleavage and apoptosis, but did not affect shikonin-mediated ROS production. Additionally, inhibition of caspase activation completely blocked shikonin-induced apoptosis, but did not appreciably modify shikonin-mediated cytochrome c release or ROS generation. Altogether, these findings demonstrate that shikonin-induced oxidative injury operates at a proximal point in apoptotic signaling cascades, and subsequently activates the stress-related JNK pathway, triggers mitochondrial dysfunction, cytochrome c release, and caspase activation, and leads to apoptosis. Our data also suggest that shikonin may be a promising agent for the treatment of CML, as a generator of ROS.
Introduction
Shikonin (C16H16O5) is a natural naphthoquinone derivative compound that is present in the root tissues of the traditional Chinese medical herb Lithospermum erythrorhizon. This herb is found throughout China, including in Southern Yun Nan, Northern Dong Bei, Western Xin Jiang and Tibet. Lithospermum erythrorhizon was first recorded in a 2 000-year-old Chinese medical material dictionary "Materia Medica of Deity of Agriculture", also called "Shen Nong Ben Cao Jing" [1] . This dictionary was compiled around the time of the Qin (225 BC-206 BC) and Han (206 BC-220 AD) dynasties. In addition, Lithospermum erythrorhizon was described as a herbal medicine in Shi-Zhen Li's (1518-1593) "Compendium of Materia Medica", which is also called "Ben Cao Gang Mu" [2] , and was written during the Ming dynasty (1368-1644). Lithospermum erythrorhizon has been broadly applied as a traditional Chinese medicine (TCM) for thousands of years in China to treat burns and to promote wound healing; it also has anti-bacterial and anti-inflammatory properties. Later, it was found that shikonins, including the individual compounds shikonin, isobutyryl shikonin, acetyl shikonin, dimethylacryl shikonin and isovaleryl shikonin, are responsible for the anti-bacterial and antiinflammatory activities of this TCM [3] [4] [5] [6] .
Recently, it was reported that shikonin induces apoptosis of various cancer cells and performs anti- cancer activities [7] [8] [9] [10] . Studies suggest that the anticancer activities of shikonin derivatives may be attributed to their ability to down-regulate anti-apoptotic Bcl-2 family members, such as Bcl-2 and Bcl-xL, generate reactive oxygen species (ROS), activate caspases [11, 12] , inhibit EGFR phosphorylation [13] and arrest the cell cycle through p53 upregulation [14] . However, the precise mechanisms employed by shikonin to repress cancer growth remain to be defined. C h r o n i c m y e l o g e n o u s l e u k e m i a ( C M L ) i s a myeloproliferative disorder characterized by increased proliferation of granulocytic cells without loss in their capacity to differentiate. This abnormality results from a reciprocal translocation between the abl oncogene on the long arm of chromosome 9 and the bcr region on the long arm of chromosome 22. This translocation, designated Bcr/Abl [9] , results in lengthening of an arm of chromosome 9 and shortening of an arm of chromosome 22. The latter chromosome is termed the Philadelphia chromosome (Ph 1 ), named after the city where it was discovered. The resulting bcr-abl fusion gene encodes a chimeric protein with strong tyrosine kinase activity. This cytogenetic hallmark (bcr/abl) is present in more than 90% of CML cases [15, 16] . CML is the first described malignancy associated with a gene translocation. Presence of the Bcr/Abl tyrosine kinase renders CML resistant to traditional therapeutic approaches, which makes Bcr/Abl an important therapeutic target. The first Bcr/Abl tyrosine kinase inhibitor, STI571 (Gleevec, imatinib mesylate) [17] , was recently presented as a revolutionary approach to CML treatment. STI571 is now the first-choice treatment for all newly diagnosed CML patients. Oral administration of STI571 results in a clinical response in more than 90% of CML patients. Importantly, the striking initial efficacy of this drug has been overshadowed by the development of clinical resistance. The mechanisms of resistance to STI571 include Bcr/Abl amplification, mutations in the Bcr/Abl kinase domain and diminished drug uptake, among others [18, 19] . Thus, it is important to search for additional approaches to treat this malignancy.
Apoptosis was originally defined by Kerr [20] as the orderly and characteristic sequence of structural changes resulting in the programmed death of the cell. Apoptosis is cell suicide achieved through well-characterized morphological and biochemical changes. Apoptosis appears to be a common mechanism of biological activity for cytotoxic agents employed in chemotherapy. There are two well-studied pathways that result in apoptosis: the cell surface death receptor pathway and the mitochondria-initiated pathway. In the cell surface death receptor pathway, death receptors detect the presence of extracellular death signals and rapidly ignite the cell's intrinsic apoptosis machinery [21] [22] [23] . These death receptors include CD95, TNFR1, avian CAR1, DR3, DR4 and DR5. In the mitochondria-initiated pathway, caspase activation is triggered by formation of the multimeric Apaf-1/cytochrome c complex, which recruits and activates procaspase-9. Activated caspase-9 cleaves and activates downstream caspases, such as caspase-3, -6 and -7. The release of mitochondrial cytochrome c is regulated by Bcl-2 family proteins, including the antiapoptotic proteins Bcl-2, Bcl-xL and Mcl-1 and the proapoptotic proteins Bax, Bad, Bak and Bid [24] [25] [26] [27] [28] [29] .
ROS are continually generated and eliminated in biological systems. They play important roles in a variety of normal biochemical functions and abnormal pathological processes. Excessive production of ROS in the cell is known to induce apoptosis [30, 31] . The ability of ROS to inflict severe cellular damage and cause cell death has been exploited as an approach to kill cancer cells. ROS generation has also been shown to play an important role in apoptosis induced by treatment with cisplatin, bleomycin, UV irradiation and Bortezomib (PS341), a proteosome inhibitor recently approved by the FDA for the treatment of multiple myeloma [32] .
c-Jun-N-terminal kinase (JNK) is a member of the mitogen-activated protein (MAP) kinase family. Increasing evidence indicates a crucial role of JNK in mitochondrial dysfunction and the subsequent initiation of apoptosis. More specifically, apoptosis is achieved by JNK-initiated release of apoptosis-regulating factors, such as cytochrome c and Smac/DIABLO [33, 34] , JNK-mediated inactivation of anti-apoptotic proteins, JNK-mediated activation of pro-apoptotic Bcl-2 family proteins [35, 36] and JNK-induced expression of proapoptotic proteins, such as Bim [37] .
Although the efficacy of shikonin and its derivatives has been broadly studied, their precise mode of action and the molecular basis of their anti-cancer activities remain to be elucidated. Here, we report that a shikonin induces apoptosis of CML cells by the following processes: ROS generation, JNK/c-JUN activation, mitochondrial dysfunction, cytochrome c release and caspase activation. The present data also suggest that shikonin may serve as a novel agent for the treatment of CML as it induces excessive ROS production.
Results and Discussion

Shikonin induces apoptosis of CML cells in a dose-and time-dependent manner
Shikonin, the chemical structure [3, 11] of which is shown in Figure 1A , is a natural naphthoquinone-derived compound present in the root tissues of the Chinese herb Lithospermum erythrorhizon. Shikonin induces apoptosis in various cancer cell lines and performs anti-tumor activity in vivo [7] [8] [9] [10] 
Shikonin-induced apoptosis of CML cells involves both mitochondria and caspases
Shikonin has been reported to induce apoptosis through a mitochondria-and caspase-mediated pathway in human colorectal carcinoma cells [11] , and through a mitochondria-independent pathway in human SK-Hep-1 hepatoma cells [12] . To investigate whether mitochondria are involved in shikonin-induced apoptosis of CML cells, the percentage of cells that exhibit "low" 3,3-dihexylo xacarbocynine (DiOC6) uptake, which reflects a loss of mitochondrial membrane potential (∆ψm), was examined using the DiOC6 staining assay after shikonin treatment. The data obtained from flow cytometry experiments Shikonin (nM) demonstrate that shikonin mediates a mitochondrial permeability transition (loss of ∆ψm) in K562 cells (Figure 2A ), which suggests that mitochondria are involved in shikonin-induced apoptosis. To determine the contribution of caspases to this process, K562 cells were treated with shikonin in the absence or presence of a broad-spectrum caspase inhibitor, BOC-fmk, for 24 h. Shikonin-induced apoptosis was completely blocked by BOC-fmk treatment ( Figure 2B ). Furthermore, western blotting analysis indicated that shikonin treatment resulted in a profound mitochondrial release of cytochrome c and Smac/DIABLO, cleavage of myeloid cell leukemia-1 (Mcl-1, an anti-apoptotic protein in the Bcl-2 family), caspase-3 and -9 and PARP. The release of Smac/DIABLO and cleavage of Mcl-1, caspase-3 and -9 and PARP were blocked by BOC-fmk, while the release of cytochrome c was not affected by BOC-fmk ( Figure  2C ). Altogether, these results indicate that cytochrome c release, which is an indicator of mitochondrial injury, is upstream of caspase activation and that Mcl-1 attenuation is secondary to caspase activation, as it is a caspasemediated event. In this case, cleavage of Mcl-1 may amplify the extent of apoptosis induced by shikonin. This hypothesis is based on previous studies that demonstrated that caspase-mediated cleavage of Mcl-1 inhibits its antiapoptotic function [38] . In addition, we noted that BOCfmk did not completely block cleavage of caspase-9. This is expected since this caspase is autocatalytic. Together, these results suggest that shikonin-induced apoptosis in K562 cells is mediated by a pathway that involves mitochondria injury, cytochrome c release and caspase activation.
ROS trigger multiple signaling cascades involved in shikonin-induced apoptosis
A previous study reported that shikonin induces ROS formation, but that it does not induce a mitochondrial permeability transition in the course of inducing apoptosis of human SK-Hep-1 hepatoma cells [12] . However, the results shown in Figure 2A demonstrate that mitochondria are involved in shikonin-induced apoptosis of K562 cells. In order to test whether shikonin leads to ROS generation in CML cells, K562 cells were treated with shikonin, as indicated in Figure 3A . Rapid generation of ROS was detected at 1 h following shikonin treatment. Importantly, ROS production was markedly blocked by LNAC treatment (L-N-acetylcysteine, free radical scavenger) (P< 0.001) ( Figure 3A) . Consequently, apoptosis induced by shikonin was also completely abolished by LNAC treatment ( Figure 3B ). It is known that ROS activates multiple signaling pathways, including MAPK and Akt signal transduction cascades [30] . Western blot analysis was employed to evaluate the activity of MAPK and Akt signal transduction pathways after shikonin treatment ( Figure 3C ). The results show that shikonin-induced ROS generation was followed by striking increases in the levels of phospho-JNK, phospho-c-JUN and phospho-p38, a significant decrease in the level of phospho-Erk1 (44 kDa), as well as a profound release of cytochrome c, and cleavage of caspase-3 and -9 and PARP. LNAC treatment completely reversed JNK and p38 phosphorylation, cytochrome c release and caspase cleavage, suggesting that ROS generation is upstream of the examined mediators. Moreover, LNAC completely blocked shikonin-mediated Smac/DIABLO release (data not shown). However, there was no appreciable modification of phosphorylation of Erk2 (42 kDa), Akt or GSK 3 after LNAC treatment. If ROS generation is the proximal event of JNK and p38 activation in shikonin-treated K562 cells, inhibition of JNK, p38 and caspase activity would not influence ROS generation. To test this hypothesis, K562 cells were exposed to shikonin in the absence or presence of JNK, p38 and caspase inhibitors, independently. As shown in Figure 3D , ROS generation was not appreciably modified after addition of the inhibitors (SP600125, a specific JNK inhibitor; SB203580, a specific p38 inhibitor; and BOC-fmk, a pan-caspase inhibitor). These results are consistent with the prediction that ROS generation is the initial event and that it precedes activation of the MAPK and Akt signaling cascades. Results from parallel experiments performed in LAMA84 cells showed that a significant amount of ROS (e.g., 9-fold increase) was generated after only 1 h of exposure to shikonin, which was blocked by LNAC (data not shown).
JNK activation contributes to shikonin-induced apoptosis of CML cells
The preceding results indicated that shikonin activated JNK, c-JUN and p38 signaling cascades ( Figure 3C ). We next tested the functional roles of these signals in druginduced apoptosis. K562 cells were treated with shikonin in the absence or presence of pharmacological inhibitors of JNK and p38. A time-course study showed that JNK activation persists after treatment with 0.5 mM shikonin ( Figure 4A ). SP600125, a specific JNK inhibitor, markedly blocked shikonin-induced apoptosis (P< 0.001). However, SB203580, a specific p38 inhibitor, did not appreciably modify drug-induced apoptosis ( Figure 4B ). Western blotting analysis showed that treatment with SP600125 markedly blocked shikonin-induced c-JUN phosphorylation, cytochrome c release, and cleavage of caspase-3 and -9 and PARP, while SB203580 had no effect on any of these events ( Figure 4C) .
In order to determine whether JNK activation contributes to shikonin-induced apoptosis, K562 cells were transfected with a JNK1 short interfering RNA (siRNA) and then treated with shikonin. Western blotting analysis indicated that knock-down of JNK1 markedly blocked cytochrome c release and PARP cleavage ( Figure 4D ) as well as the induction of apoptosis ( Figure  4E ). In addition, decreased JNK1 activity, achieved by JNK siRNA-mediated knock-down or JNK inhibition by SP600125, did not affect shikonin-mediated ROS generation (data not shown). Together, these data suggest that activation of JNK, and not p38, plays a functional role in shikonin-induced apoptosis. These results also indicate that JNK activation is upstream of cytochrome c release, caspase activation and PARP cleavage.
Putative model of signaling cascades in shikonin-induced apoptosis of CML cells
The above results suggest a model in which shikonin induces apoptosis by inducing production of ROS, which subsequently leads to activation of JNK, release of cytochrome c, and cleavage of caspases and PARP. Blockage of ROS generation, JNK activation and caspase activation affected the corresponding downstream cascades ( Figure 5 ). ROS generation by shikonin represents the proximal and initiating event in druginduced apoptosis.
In summary, our results indicate that apoptosis induced by shikonin treatment of CML cells is caused by the rapid generation of ROS, which triggers JNK phosphorylation, mitochondrial injury and caspase activation. ROS generation and JNK activation play critical roles in shikonin-induced apoptosis. This result also suggests that shikonin may serve as a novel agent for CML treatment by inducing excessive production of ROS.
Materials and Methods
Cells
The K562 cell line was purchased from American Type Culture Collection, Rockville, MD. The LAMA84 cell line was purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Sub-confluent, logarithmically growing cells were placed in sterile plastic T-flasks, to which the designated drugs were added. The flasks were then incubated in a humidified incubator with 5% CO2 at 37 °C for various lengths of time, as indicated.
Materials
Shikonin was obtained from Shanghai TCI Chemical Co. (Shanghai, China); this chemical had a purity of >97%. BOC-D-fmk was purchased from Enzyme System Products (Livermore, CA). LNAC, DiOC6, 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI), PI and SP600124 were obtained from Sigma Chemical Co. (Beijing, China).
Assessment of apoptosis
Following drug treatment, apoptotic cells were detected by DAPI staining, which allowed for identification of apoptotic nuclear changes as described previously [39] . Briefly, 1 × 10 5 cells were harvested and washed with phosphate-buffered saline (PBS) and then fixed with 1% glutaraldehyde at room temperature for 30 min. After washing with PBS, cells were re-suspended in 20 ml of PBS and mixed with 5 ml of a 10 mg/ml stock solution of DAPI.
Cell suspensions were mounted on slides. Cells were visualized under microscope with a 360-370 nm excitation light and 420-460 nm emission filter; apoptotic cells appeared with characteristic condensed and fragmented nuclei. 
Annexin V/PI staining
To confirm the results of morphological analysis, Annexin V/PI staining was employed. For Annexin V/PI assays, cells were stained with Annexin V-FITC and PI and then monitored for apoptosis by flow cytometry in accordance with the manufacturer' s protocol (BD PharMingen, San Diego, CA, USA). Briefly, 0.5 ×10 6 cells were washed twice with PBS and stained with 5 ml of Annexin V-FITC and 10 ml of PI (5 mg/ml) in 1× binding buffer (10 mM HEPES, pH 7.4, 140 mM NaOH, 2.5 mM CaCl2) for 15 min at room temperature in the dark. Apoptotic cells were quantified using a FACScan cytofluorometer. Both early apoptotic (Annexin V-positive, PI-negative) and late apoptotic (double positive of Annexin V and PI) cells were detected.
Assessment of mitochondrial membrane potential (∆ψm)
Mitochondrial membrane potential was monitored using the fluorescent dye DiOC6. For each condition, 4 × 10 5 cells were incubated for 30 min at 37 °C in 1 ml of 40 nM DiOC6 and subsequently analyzed using a FACScan cytofluorometer with excitation and emission settings of 488 and 525 nm, respectively. The percentage of cells exhibiting a low level of DiOC6 uptake exhibited a loss of mitochondrial membrane potential.
Detection of ROS
Generation of ROS was assessed using fluorescent probe dihydroethidium (DHE) staining, as was previously described [40] . In the presence of superoxide (O2 − ), DHE is oxidized to fluorescent products, which are monitored by flow cytometry. Briefly, cells were incubated with 20 mM DHE in tissue culture medium for 30 min at 37°C, and then washed, re-suspended in PBS, and subsequently monitored by flow cytometry.
Western blot analysis
Following drug treatment, cell lysates were prepared and Western blot analysis was performed with primary antibodies, as described previously [40] . The following antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, USA): caspase 9, cleaved caspase 3, cytochrome c, phospho-ERK1/2, phospho-JNK, phospho-c-JUN (Ser73), phospho-Akt, phospho-p38 and actin. To ensure equivalent loading and transfer, all blots that had been probed for proteins other than actin were stripped and re-probed with an antibody against actin. The western blots shown in the figures are representative of three independent experiments unless otherwise indicated.
Assessment of cytochrome c release from mitochondria
Following drug treatment, the release of cytochrome c from mitochondria was analyzed by a selective digitonin permeabilization method. Briefly, 4 × 10 6 cells per condition were re-suspended in 50 ml of permeabilization buffer (containing 75 mM NaCl, 8 mM Na2PO4, 1 mM NaH2PO4, pH 7.4, 250 mM sucrose (added fresh before use), 1 mM EDTA, 700 mg/ml digitonin) (final concentration of digitonin 35 mg/4 × 10 6 cells). Cells were incubated in the above permeabilization buffer at room temperature for 1 min, after which the pellet was removed by centrifugation for 3 min at 13 000 × g, and the supernatant containing cytochrome c protein was obtained.
siRNA-mediated knock-down
A JNK1-specific siRNA (5′-GCAGAAGCAAACGTGAC AACA-3′) and a negative control siRNA (Catalog# AM4635) were purchased from Ambion (Austin, TX, USA). Cells were transfected with siRNAs at a final concentration of 30 nM using siPORT™ NeoFX™ Transfection Agent, following the manufacturer's protocol.
Statistical analysis
All of the data are expressed as mean ± SD of three individual experiments. Differences between groups were determined using the Student's t test for unpaired observations. P < 0.05 was considered significant.
